

Corporate Accountability for Tax Expenditures Act 93-552

Annual Project Progress Reports for 2021

Novartis Gene Therapies, Inc. fka AveXis, Inc.

Libertyville

I. Development Assistance Agreements Awarded in 2018

	Assistance Amount	Agreement Number
EDGE Tax Credit	1,170,037.69	18 ZCA008

II. Organization/Project Site Information

Chief Officer or authorized designee	Eamon Fitzmaurice
Title	Controller
Address	2512 South Tricenter Blvd
	Durham, NC 27713
	USA
Phone	9198804412
E-mail	eamon.fitzmaurice@novartis.com
Standard Industrial Classification Number (SIC#)	2836
North American Industry Classification System (NAICS)	325414

III. Did the recipient's use of the State Funding reduce employment at any other site in Illinois? No

Corporate Accountability for Tax Expenditures Act 93-552

Annual Project Progress Reports for 2021

Novartis Gene Therapies, Inc. fka AveXis, Inc.

Libertyville

IV. Job Creation and Retention Data

Program Type EDGE Tax Credit

Agreement Number 18 ZCA008

Assistance Amount 1,170,037.69

Report Header Definitions	
Wages	Average Annual Salary by Classifications
Full-Time	Permanent Full-Time
+/-	Gain or (Loss)

Number of Employees At the Time of Application

Job Classification	Avg Annual Salary	Positions	Full-Time	Part-Time	Temporary
Administrative	166300.00	214	214	0	0
Director/Finance/HR/Engineering	0.00	0	0	0	0
Manager	0.00	0	0	0	0
Production/Quality	0.00	0	0	0	0
Warehouse/Supervisor	0.00	0	0	0	0
Totals:		214	214	0	0

Number of Employees As of the Date of the Report (12/31/2021)

Job Classification	Avg Annual Salary	Positions	Full-Time	+/-	Part-Time	+/-	Temporary	+/-
Administrative	104000.00	35	35	-179	0	0	0	0
Director/Finance/HR/Engineering	180000.00	242	242	242	0	0	0	0
Manager	155000.00	57	57	57	0	0	0	0
Production/Quality	111000.00	134	134	134	0	0	0	0
Warehouse/Supervisor	76000.00	20	20	20	0	0	0	0
Totals:		488	488	274	0	0	0	0

Corporate Accountability for Tax Expenditures Act 93-552

Annual Project Progress Reports for 2021

Novartis Gene Therapies, Inc. fka AveXis, Inc.

Libertyville

Number of Jobs Stated in the Agreement that would be Created at the Site as a Result of Assistance

Job Classification	Avg Annual Salary	Positions	Full-Time	Part-Time	Temporary
Clinical	203461.54	8	8	0	0
Commercial Operations	161111.11	4	4	0	0
Corporate Project Management	150000.00	2	2	0	0
Finance	110714.29	4	4	0	0
Human Resources	170000.00	2	2	0	0
IT	195000.00	2	2	0	0
Manufacturing	96041.00	24	24	0	0
Regulatory/Quality	220875.00	4	4	0	0
Totals:		50	50	0	0

Number of Jobs Stated in the Agreement that would be Retained at the Site as a Result of Assistance

Job Classification	Avg Annual Salary	Positions	Full-Time	Part-Time	Temporary
NONE	0.00	0	0	0	0
NONE	0.00	0	0	0	0
Totals:		0	0	0	0

Number of Full-Time Permanent Employees Anticipated To Be Hired at this Site on 12/31/2021

Job Classification	Anticipated Starting Dates	Number of Positions to be Hired in this Category	Average Annual Wage per New Employee	Total New Payroll to be Created
NONE		0	\$0.00	\$0.00
Totals:		0		\$0.00

Job Creation Data Explanatory Notes

If the change (gain/loss) in the number of full-time permanent employees as of the date of the report plus the number of full-time permanent employees anticipated to be hired after date of the report does not equal the number of full-time permanent employees stated in the Agreement that would be created at the site as a result of the assistance, then please explain why not:

Corporate Accountability for Tax Expenditures Act 93-552

Annual Project Progress Reports for 2021

Novartis Gene Therapies, Inc. fka AveXis, Inc.

Libertyville

The company has exceeded their hiring commitments.

Corporate Accountability for Tax Expenditures Act 93-552

Annual Project Progress Reports for 2021

Novartis Gene Therapies, Inc. fka AveXis, Inc.

Libertyville